Abstract
Systemic lupus erythemaotsus (SLE) is an autoimmune disease involving multiple organ systems and characterized by anti-nuclear antibodies. While T cells and dendritic cells may play major roles in SLE, several lines of evidence strongly suggest a central role for B cells. This article will review the role of B cells in human SLE as well as the currently available data on the treatment of SLE by depleting B cells with anti-CD20 (rituximab).
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20 / metabolism*
-
Autoantibodies / metabolism
-
B-Lymphocytes / immunology
-
Humans
-
Infections / etiology
-
Lupus Erythematosus, Systemic / immunology*
-
Lupus Erythematosus, Systemic / therapy*
-
Lymphocyte Depletion / adverse effects
-
Plasma Cells / immunology
-
Rituximab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20
-
Autoantibodies
-
Rituximab